IRX-010 is under clinical development by ImmunoRx Pharma and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IRX-010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IRX-010 overview
IRX-010 is under development for the treatment of inflammatory disease. It is administered through intravenous route.
ImmunoRx Pharma overview
ImmunoRx Pharma a company that plans to develop a first-in-class antibody, to proof-of-concept, with the potential to treat certain types of chronic inflammatory diseases, including ulcerative colitis, rheumatoid arthritis, and Crohn’s disease. It is headquartered in Wilmington, Delaware, the US.
For a complete picture of IRX-010’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.